Bristol Myers Squibb Space Research

Bristol Myers Squibb Space Research refers to the ISS-based drug-development program of Bristol Myers Squibb (BMS), the pharmaceutical group founded in 1887, registered in Princeton, New Jersey, listed on the NYSE as BMY, and employing about 32,500 people as of 2025. BMS studies protein crystallization and alternative drug-delivery methods aboard the International Space Station National Laboratory, with a specific goal of finding ways to replace scheduled medication infusions with quick injections for patients.

The company's main ISS research vehicle has been Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) facility, a commercial service provider platform used to examine small-molecule compound crystallization in microgravity. BMS payloads have flown on multiple SpaceX Commercial Resupply Services missions to the station, including CRS-27 in March 2023, continuation supplies on CRS-28 in May 2023, and further work on CRS-31 in November 2024. The company has also run tissue-chip investigations aboard the ISS to gather drug-development insights that are difficult to obtain in terrestrial cell culture.

BMS is represented on the ISS National Laboratory's Applied Research and Development Subcommittee, with the company's participation attributed to representatives including Robert Garmise. As with other large drugmakers using the station -- Sanofi, Merck, Eli Lilly, GlaxoSmithKline and AstraZeneca among them -- this space research is a specific, ongoing R&D program rather than a separately incorporated business.